Investigation of the insulin-like growth factor-1 signaling pathway in localized Ewing sarcoma: A report from the Children's Oncology Group

Cancer

Volumn 117, Issue 21, 2011, Pages 4966-4976

  Borinstein, Scott C ^a   Barkauskas, Donald A ^b   Krailo, Mark ^c   Scher, Daniel ^d   Scher, Lauren ^d   Schlottmann, Silke ^d   Kallakury, Bhaskar ^d   Dickman, Paul S ^e   Pawel, Bruce R ^f   West, Daniel C ^g   Womer, Richard B ^h   Toretsky, Jeffrey A ^d  

^a VANDERBILT UNIVERSITY   (United States)

^b CHILDREN S ONCOLOGY GROUP   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d GEORGETOWN UNIVERSITY   (United States)

^e PHOENIX CHILDREN'S HOSPITAL   (United States)

^f CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Akt; Ewing sarcoma; forkhead box protein O1; insulin like growth factor 1; insulin like growth factor binding protein 3; p70S6 kinase; protein tyrosine phosphatase L1

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 13; PROTEIN KINASE B; S6 KINASE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TRANSCRIPTION FACTOR FKHR; VINCRISTINE;

ADULT; ARTICLE; CARCINOGENESIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; EVENT FREE SURVIVAL; EWING SARCOMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION;

ADOLESCENT; ADULT; AGE FACTORS; CHILD; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; SARCOMA, EWING; SIGNAL TRANSDUCTION;

EID: 80054814917     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26112     Document Type: Article

References (39)

1. Horner MJ RL, Krapcho M, Neyman N, et al. eds. SEER Cancer Statistics Review, 1975-2006. Bethesda, MD: National Cancer Institute; 2009.
2. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003; 348: 694-701. (Pubitemid 36237038)
3. Womer RB, West DC, Krailo MD, Dickman PS, Pawel B, for the Children's Oncology Group AEWS0031 Committee. Randomized comparison of every-2-week v. every-3-week chemotherapy in Ewing sarcoma family tumors (ESFT) [abstract]. J Clin Oncol. 2008; 26 (15s). Abstract 10504.
4. Riggi N, Stamenkovic I,. The Biology of Ewing sarcoma. Cancer Lett. 2007; 254: 1-10. (Pubitemid 47058800)
5. Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature. 1992; 359: 162-165.
6. Deneen B, Denny CT,. Loss of p16 pathways stabilizes EWS/FLI1 expression and complements EWS/FLI1 mediated transformation. Oncogene. 2001; 20: 6731-6741. (Pubitemid 33020602)
7. Lessnick SL, Dacwag CS, Golub TR,. The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts. Cancer Cell. 2002; 1: 393-401. (Pubitemid 41039140)
8. Riggi N, Suva ML, Suva D, et al. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. Cancer Res. 2008; 68: 2176-2185. (Pubitemid 351521790)
9. Toretsky JA, Kalebic T, Blakesley V, LeRoith D, Helman LJ,. The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem. 1997; 272: 30822-30827. (Pubitemid 27527522)
10. Scotlandi K, Benini S, Sarti M, et al. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res. 1996; 56: 4570-4574. (Pubitemid 26338048)
11. Yee D, Favoni RE, Lebovic GS, et al. Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor. J Clin Invest. 1990; 86: 1806-1814.
12. Scotlandi K, Benini S, Nanni P, et al. Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice. Cancer Res. 1998; 58: 4127-4131. (Pubitemid 28440569)
13. Riggi N, Cironi L, Provero P, et al. Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res. 2005; 65: 11459-11468. (Pubitemid 41821703)
14. Cironi L, Riggi N, Provero P, et al. IGF1 is a common target gene of Ewing's sarcoma fusion proteins in mesenchymal progenitor cells [serial online]. PLoS One. 2008; 3: e2634.
15. Pullen N, Thomas G,. The modular phosphorylation and activation of p70s6k. FEBS Lett. 1997; 410: 78-82.
16. Martins AS, Ordonez JL, Garcia-Sanchez A, et al. A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: in vitro and in vivo study. Cancer Res. 2008; 68: 6260-6270.
17. Biggs WH 3rd, Meisenhelder J, Hunter T, Cavenee WK, Arden KC,. Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc Natl Acad Sci U S A. 1999; 96: 7421-7426. (Pubitemid 29299677)
18. Dromard M, Bompard G, Glondu-Lassis M, Puech C, Chalbos D, Freiss G,. The putative tumor suppressor gene PTPN13/PTPL1 induces apoptosis through insulin receptor substrate-1 dephosphorylation. Cancer Res. 2007; 67: 6806-6813. (Pubitemid 47105528)
19. Jones JI, Clemmons DR,. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995; 16: 3-34.
20. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M,. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004; 363: 1346-1353. (Pubitemid 38529873)
21. Prieur A, Tirode F, Cohen P, Delattre O,. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol. 2004; 24: 7275-7283. (Pubitemid 39014452)
22. Kolb EA, Gorlick R,. Development of IGF-IR inhibitors in pediatric sarcomas. Curr Oncol Rep. 2009; 11: 307-313.
23. Toretsky JA, Steinberg SM, Thakar M, et al. Insulin-like growth factor type 1 (IGF-1) and IGF binding protein-3 in patients with Ewing sarcoma family of tumors. Cancer. 2001; 92: 2941-2947.
24. Bishop YMM, Feinberg SE, Holland PW,. Discrete Multivariate Analysis. Cambridge, MA: MIT Press; 1975.
25. Kalbfleisch JD, Prentice RL,. The Statistical Analysis of Failure Time Data. New York: John Wiley and Sons; 2002.
26. Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol. 2000; 18: 3108-3114.
27. Yock TI, Krailo M, Fryer CJ, et al. Local control in pelvic Ewing sarcoma: analysis from INT-0091-a report from the Children's Oncology Group. J Clin Oncol. 2006; 24: 3838-3843. (Pubitemid 46655603)
28. Abaan OD, Levenson A, Khan O, Furth PA, Uren A, Toretsky JA,. PTPL1 is a direct transcriptional target of EWS-FLI1 and modulates Ewing's Sarcoma tumorigenesis. Oncogene. 2005; 24: 2715-2722. (Pubitemid 40593099)
29. Atzori F, Tabernero J, Cervantes A, et al. A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (MAb) in patients (pts) with advanced solid tumors [abstract]. J Clin Oncol. 2008; 26 (15s). Abstract 3519.
30. Kolb EA, Gorlick R, Houghton PJ, et al. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2008; 50: 1190-1197. (Pubitemid 351555543)
31. Houghton PJ, Morton CL, Gorlick R, et al. Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2010; 54: 921-926.
32. Naing A, LoRusso P, Gupta S, et al. Dual inhibition of IGFR and mTOR pathways [abstract]. J Clin Oncol. 2010; 28 (15s). Abstract 3007.
33. Kurzrock R, Patnaik A, Aisner J, et al. A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin Cancer Res. 2010; 16: 2458-2465.
34. Pappo AS, Patel S, Crowley J, et al. Activity of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R), in patients (pts) with recurrent or refractory Ewing's sarcoma family of tumors (ESFT): results of a phase II SARC study [abstract]. J Clin Oncol. 2010; 28 (15s). Abstract 10000.
35. Olmos D, Postel-Vinay S, Molife LR, et al. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol. 2010; 11: 129-135.
36. Tolcher AW, Sarantopoulos J, Patnaik A, et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol. 2009; 27: 5800-5807.
37. Tap WD, Demetri GD, Barnette P, et al. AMG 479 in relapsed or refractory Ewing's family tumors (EFT) or desmoplastic small round cell tumors (DSRCT): phase II results [abstract]. J Clin Oncol. 2010; 28 (15s). Abstract 10001.
38. Dong J, Demarest SJ, Sereno A, et al. Combination of 2 insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor response. Mol Cancer Ther. 2010; 9: 2593-2604.
39. Erkizan HV, Kong Y, Merchant M, et al. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nat Med. 2009; 15: 750-756.